Caris Life Sciences Secures FDA Approval for Tumor Profiling Test.

Caris Life Sciences has secured FDA approval for its MI Cancer Seek platform, a revolutionary tumor profiling test that combines whole exome and transcriptome sequencing for adult and pediatric tumors. The platform enables comprehensive tumor profiling from minimal samples, improving accuracy, access, and turnaround time. Caris is also advancing blood-based diagnostics with Caris Assure and expanding collaborations to accelerate tumor profiling adoption in clinical practice.